📄 $CSTL 10-Q — what changed
MD&A now says: "Our revenue is primarily generated by our DecisionDx-Melanoma risk stratification test for cutaneous melanoma ("CM") and our TissueCypher risk stratification test for BE."
📈 Full redline → https://www.formdelta.com/ticker/CSTL
@formdelta.bsky.social